Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies  >  All News

News : Companies
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

AXOVANT GENE THERAPIES LTD. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
03/26/2020 | 03:34pm EDT

Item 5.03 Amendment to Articles of Incorporation of Bye-laws.

On February 17, 2020, the board of directors of Axovant Gene Therapies Ltd. approved, and on February 19, 2020, the holder of a majority of our issued and outstanding common shares approved, an amendment and restatement of our Second Amended and Restated Bye-laws to be the Third Amended and Restated Bye-Laws, which amends and restates the Second Amended and Restated Bye-laws to, among other things:

(i) remove the provisions related to reducing the voting power of certain U.S. persons holding, directly, indirectly or constructively, 9.5% or more of the total voting power of our issued share capital;

(ii) remove the provisions which prohibited certain transactions between us and interested shareholders unless approved by our board of directors and a supermajority of shareholders; and



(iii)    make certain other administrative changes.


The above description is only a summary and is qualified in its entirety by reference to the full text of the Third Amended and Restated Bye-Laws, a copy of which is provided in Appendix A to the Definitive Information Statement on DEF 14C filed with the Securities and Exchange Commission on March 2, 2020.

The effective date of the adoption of the Third Amended and Restated Bye-laws is March 22, 2020.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



 Exhibit No. Description




   3.1      Third Amended and Restated Bye-laws (incorporated by reference to
          Appendix A to the Definitive Information Statement on DEF 14C filed with
          the Securities and Exchange Commission on March 2, 2020).

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news "Companies"
05:18aRENEURON : Exosome Research Collaboration
AQ
05:18aZENTIVA S A : extends commercial footprint by completing acquisition of CEE business from Alvogen
AQ
05:18aNAGASE : & CO., LTD. - Notice of NAGASE Group Response to the Declaration of State of Emergency
AQ
05:18aMERCK : Receives Priority Review from FDA for Second Application for KEYTRUDA Based on Biomarker, Regardless of Tumor Type
AQ
05:18aELI LILLY AND COMPANY : - New $35 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-19 Crisis in U.S
AQ
05:18aRHYTHM PHARMACEUTICALS : to Present Virtually at Needham and Co. 19th Annual Healthcare Conference
AQ
05:18aFRENCKEN : Deferment Of Annual General Meeting And Extraordinary General Meeting On 23 April 2020
PU
05:18aBYD : Vehicle Sales Decline Eased in March
DJ
05:17aALNYLAM PHARMACEUTICALS : Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration
AQ
05:17aONO PHARMACEUTICAL : Announcement on Election of Provisional Audit and Supervisory Board Member
AQ
Latest news "Companies"